Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
15
Recruiting, any sponsor type, condition "hypertriglyceridemia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed160
15 trials
Showing 1 to 15, recently updated first.
- Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolPivotal-lookingRecruiting
Marea TherapeuticsIndustry
NCT07028749 · 316 participants (planned) · Start Jun 30, 2025 · Primary completion Nov 2027
Drug: MAR001; Placebo · For: Hypertriglyceridemia
Sites: Anniston, Alabama; Mobile, Alabama; Little Rock, Arkansas · 62 sites in all
- Pemafibrate for Symptomatic ICAS RCTPivotal-lookingRecruiting
Tokyo Women's Medical UniversityAcademic, hospital or other
NCT07562178 · 270 participants (planned) · Start May 26, 2026 · Primary completion Mar 31, 2028
Drug: Pemafibrate · For: Intracranial Atherosclerotic Disease (ICAD); Hypertriglyceridaemia; Stroke (CVA) or TIA
Sites: Toyoake, Japan; Yachiyo, Japan; Yoshida, Japan · 42 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07269210 · 60 participants (planned) · Start Dec 8, 2025 · Primary completion Mar 2027
Drug: Solbinsiran; Placebo · For: Severe Hypertriglyceridemia
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 41 sites in all
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07604974 · 72 participants (planned) · Start May 12, 2026 · Primary completion Sep 2027
Drug: ION775 · For: Hypertriglyceridemia; Severe Hypertriglyceridemia
Sites: Lincoln, California; Aurora, Colorado; Boca Raton, Florida · 18 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT06451770 · 132 participants (planned) · Start Oct 30, 2024 · Primary completion Dec 2027
Drug: VERVE-201 · For: Hypercholesterolemia; Hypertriglyceridemia; Refractory Hyperlipidemia
Sites: Garden Grove, California; Clearwater, Florida; Miami Lakes, Florida · 18 sites in all
- A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With HypertriglyceridemiaPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07799688 · 400 participants (planned) · Start Sep 11, 2026 · Primary completion Oct 15, 2028
Drug: HRS-7249 Injection; HRS-7249 Injection · For: Hyperlipidemia
Sites: Jinan, China; Shanghai, China
Meir Medical CenterAcademic, hospital or other
NCT06206759 · 2,000 participants (planned) · Start May 1, 2024 · Primary completion Feb 1, 2027
Drug: administration of vitamin C · For: Hypertriglyceridemia
Sites: Kfar Saba, Israel
General Hospital of Shenyang Military RegionAcademic, hospital or other
NCT07388420 · 60 participants (planned) · Start Jan 2, 2026 · Primary completion Dec 31, 2026
Drug: Evolocumab 140 MG/ML [Repatha]; Conventional lipid-lowering therapy · For: Hypertriglyceridemia Induced Acute Pancreatitis
Sites: Shenyang, China
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT06880770 · 288 participants (planned) · Start Apr 24, 2025 · Primary completion Mar 2029
Drug: Plozasiran; Placebo · For: Severe Hypertriglyceridemia
Sites: Los Angeles, California; Santa Clarita, California; New Haven, Connecticut · 140 sites in all
- A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasRecruiting
CRISPR Therapeutics AGIndustry
NCT07491172 · 90 participants (planned) · Start Jun 21, 2024 · Primary completion Jun 2027
Drug: CTX310 · For: Cardiovascular; Metabolic Disease; Dyslipidemias and 7 more
Sites: Hialeah, Florida; Jacksonville, Florida; Orlando, Florida · 17 sites in all
- Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCTPivotal-lookingRecruiting
Jianyin ZhouAcademic, hospital or other
NCT07720232 · 180 participants (planned) · Start Jan 18, 2026 · Primary completion Jan 18, 2028
Drug: Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE); Standard Care (in control arm) · For: Hypertriglyceridemic Acute Pancreatitis; Acute Pancreatitis, Hypertriglyceridemia-induced; Hyperlipidemia
Sites: Xiamen, China
- CS-121 APOC3 Base Editing in FCSRecruiting
CorrectSequence Therapeutics Co., LtdIndustry
NCT07176923 · 15 participants (planned) · Start Oct 15, 2025 · Primary completion Dec 2026
Drug: CS-121 · For: Familial Chylomicronemia Syndrome (FCS)
Sites: Hefei, China
Shanghai JMT-Bio Inc.Industry
NCT07140809 · 48 participants (planned) · Start Sep 9, 2025 · Primary completion Jul 31, 2026
Drug: JMT202 injection · For: Hypertriglyceridemia
Sites: Beijing, China
- A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolRecruiting
Marea TherapeuticsIndustry
NCT07199309 · 30 participants (planned) · Start Sep 26, 2025 · Primary completion Jul 2026
Drug: MAR001; Placebo · For: Hypertriglyceridemia
Sites: Chula Vista, California
The Miriam HospitalAcademic, hospital or other
NCT06494488 · 80 participants (planned) · Start Jul 10, 2025 · Primary completion Aug 1, 2027
Drug: EPA; DHA · For: Lipid Metabolism Disorders; Hypertriglyceridemia
Sites: Providence, Rhode Island
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.